Pre-filled Syringes San Francisco Conference 2020

SMi Group 14 - 15 September 2020, San Francisco, USA.
The global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry, is expected to exceed $9.7 billion by 2025. With that in mind, this event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry.

As part of SMi's leading Injectable conference series, we will assess digital health and connected devices, biologics, biosimilars and biocompatibility for drug device combination products, platform and device selection, regulatory insights and explore the West Coast's biotech innovators. This two-day agenda offers you peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.

Plus, a workshop on human factors and risk management:

  • Integration of Human Factors Engineering processes in risk management saves time and money in product development
  • Effective identification of use-related risk helps inform constructive design decisions
  • Mitigation of use-related risk improves treatment outcomes for end users
  • Understanding the methods used to assess use-related risk will improve the efficiency and acumen of your organization

Benefits of attending

  • EXPLORE the latest industry case studies in platform approaches and connected devices
  • GAIN insights from leading industry and regulatory experts on the pre-filled syringes environment
  • HEAR from local biotechs of San Francisco and the West Coast to learn about new innovations in the pre-filled syringes space
  • ENGAGE in the key challenges and topics of the field in two interactive half-day workshops

Chairs for 2020

  • Shannon Clark, Principal, UserWise
  • Steven Badelt, Founder and Managing Partner, Suttons Creek, Inc.

Featured 2020 speakers include

  • Kristina Lauritsen, Combination Products Regulatory Advisor, FDA/CDER
  • Manuela Gazzard, Group Executive Director Regulatory Services Healthcare, BSI
  • Christine Lynn Lanning, Distinguished Scientist, Device Area Leader, Safety Assessment/Merck & Co., Inc
  • Khaudeja Bano, Senior Medical Director, Abbott Laboratories
  • Jace Blackburn, Smart Device Engineer, Genentech
  • Michael Koby, Senior Principle Scientist, Pfi zer
  • James Leamon, Director of Biologics Device Development, Jazz Pharmaceuticals
  • Walter Goodwin, Device Engineer, Device Development & Clinical Packaging Engineering, Gilead Sciences
  • Katie Atkinson, Manager Human Factors Engineering, Bigfoot Biomedical

Early-bird rates

  • Book by 29th May and save £300
  • Book by 30th June and save £200

For further information and to register, please visit:
http://www.prefilled-sanfrancisco.com/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

Sandoz announces new global 'Act4Biosimilars' init…

Sandoz, a global leader in generic and biosimilar medicines, announced the launch of a new global initiative called 'Act4Biosimilars' to help address health inequity and ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...